Track topics on Twitter Track topics that are important to you
BioCardia (OTC: BCDA) CEO Peter Altman tells Proactive the biopharma has released data from its CardiAMP heart failure trial that shows "statistically significant" figures from the ongoing Phase 3 pivotal trial in patients with heart failure.
The Circulation Research Journal has released the first data of any pivotal cell study of heart failure ever, and Altman says this is exciting because the outcomes measure an improvement across the board in three areas, at a point where patients typically don't get better.
Altman says in heart failure, approximately 50% of patients diagnosed die at five years follow-up. Topline data from BioCardia's study, which seems to be improving patients with heart failure, is not expected to be released until Q3 2020.NEXT ARTICLE